4 reasons to use candesartan Review article
Article Sidebar
Main Article Content
Abstract
Actual guidelines of the European Society of Cardiology and the European Society of Hypertension on the management of patients with hypertension suggest five main groups of drugs used in the treatment of hypertension: angiotensin-converting enzyme inhibitors, calcium channel antagonists, angiotensin II receptor blockers, diuretics and β-blockers. Each of these groups has interesting substances that despite the same mechanism of action present certain additional properties. Candesartan, a representative group of antagonists of angiotensin II receptors have been shown to reduce morbidity and mortality in patients with heart failure, effectively lower blood pressure, reduce the risk of stroke in patients with isolated systolic hypertension, and possibly reduce the risk of development of diabetes. At the same time it is very well tolerated drug. Candesartan with its efficacy and good tolerance of the treatment is a good alternative for the treatment of a wide range of patients with hypertension.
Article Details
Copyright © by Medical Education. All rights reserved.
References
2. Mendis B., Page S.R.: Candesartan: widening indications for this angiotensin II receptor blocker? Expert Opinion on Pharmacotherapy 2009; 10(12): 1995-2007.
3. Cernes R., Mashavi M., Zimlichman R.: Differential clinical profile of candesartan compared to other angiotensin receptor blockers. Vascular Health and Risk Management 2011; 7: 749-759.
4. Carey R.M., Wang Z.Q., Siragy H.M.: Update: role of the angiotensin type-2 (AT(2)) receptor in blood pressure regulation. Current Hypertension Reports 2000; 2(2): 198-201.
5. Eguchi K., Kario K., Shimada K.: Comparison of candesartan with lisinopril on ambulatory blood pressure and morning surge in patients with systemic hypertension. The American Journal of Cardiology 2003; 92(5): 621-624.
6. Malmqvist K., Kahan T., Dahl M.: Angiotensin II type 1 (AT1) receptor blockade in hypertensive women: benefits of candesartan cilexetil versus enalapril or hydrochlorothiazide. American Journal of Hypertension 2000; 13(5 Pt 1): 504-511.
7. McMurray J.J., Ostergren J., Swedberg K. et al.: Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003; 362(9386): 767-771.
8. Granger C.B., McMurray J.J., Yusuf S. et al.: Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003; 362(9386): 772-776.
9. Papademetriou V., Farsang C., Elmfeldt D. et al.: Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE). Journal of the American College of Cardiology 2004; 44(6): 1175-1180.